Allan CM, Lim P, Robson M, Spaliviero J, Handelsman DJ. Transgenic mutant D567G but not wild-type human FSH receptor overexpression provides FSH-independent and promiscuous glycoprotein hormone Sertoli cell signaling. Am J Physiol Endocrinol Metab 296: E1022-E1028, 2009. First published March 17, 2009 doi:10.1152/ajpendo.90941.2008We have characterized the in vivo actions of human wild-type FSH receptor (FSHR) overexpressed in Sertoli cells of transgenic (Tg) mice (TgFSHRwt) compared with transgenic overexpression of the human activated mutant FSHR*D567G (TgFSHR*D567G). Testicular TgFSHRwt expression significantly elevated specific FSH binding (Ͼ2-fold, P Ͻ 0.01) relative to nontransgenic testes, similar to increased FSH binding in TgFSHR*D567G testes. Isolated TgFSHRwt Sertoli cells exhibited higher FSH-stimulated cAMP levels compared with non-Tg or TgFSHR*D567G cells but did not display the elevated FSH-independent basal cAMP levels found in TgFSHR*D567G Sertoli cells. Furthermore, Sertoli cell overexpression of TgFSHR*D567G but not TgFSHRwt allowed promiscuous cAMP responses to human chorionic gonadotropin (300 IU/ml) and TSH (30 mIU/ml), demonstrating increased constitutive signaling and altered glycoprotein hormone specificity via the intracellular D567G substitution rather than FSHR overexpression. Despite elevating Sertoli cell FSH sensitivity, overexpression of TgFSHRwt had no detectable effect upon normal testis function and did not stimulate Sertoli and germ cell development in testes of gonadotropin-deficient hypogonadal (hpg) mice, in contrast to the increased meiotic and postmeiotic germ cell development in TgFSHR*D567G hpg testes. Increased steroidogenic potential of TgFSHR*D567G hpg testes was demonstrated by elevated Cyp11a1 and Star expression, which was not detected in TgFSHRwt hpg testes. Androgen-regulated and Sertoli cell-specific Rhox5 gene expression was increased in TgFSHR*D567G but not TgFSHRwt hpg testes, providing evidence of elevated LH-independent androgen activity due to mutant FSHR*D567G. Hence, transgenic FSHR overexpression in Sertoli cells revealed that the D567G mutation confers autonomous signaling and steroidogenic activity in vivo as well as promiscuous glycoprotein hormone receptor activation, independently of FSHR overexpression alone.
FSH ACTS VIA A SPECIFIC G PROTEIN-COUPLED FSH receptor (FSHR) found in testicular Sertoli or ovarian granulosa cells (46) . Specific binding of FSH to Sertoli cell FSHR stimulates the heterotrimeric Gs protein, activating adenylate cyclase and increasing intracellular second messenger cAMP (46) . Targeted deletion of Fshr or Fshb genes in mice preserves male fertility despite reduced testis size, whereas females remain sterile (1, 13, 22) . Likewise, men with an inactivating FSHR (A198V) mutation remain fertile despite exhibiting smaller testes (50) , whereas affected women have complete infertility (6, 32, 50, 52) . While these findings suggest FSHR activity is not a prerequisite for male fertility, it is possible that mutated FSHR*A198V retains residual function (42) . Moreover, men lacking normal circulating FSH are infertile (16, 24, 25, 27, 28, 40) . FSH alone cannot initiate completion of spermatogenesis in androgen-deficient men (44) , but prepubertal FSH administration may enhance subsequent FSHϩhCG (human chorionic gonadotropin)-induced pubertal onset and testis function in hypogonadotropic hypogonadal boys (41) , suggesting that FSH has a key role in human spermatogenesis (reviewed in Ref. 4 ). In addition, FSH increases Sertoli, spermatogonia, and meiotic spermatocyte numbers and has synergistic effects with androgen on postmeiotic development in hypogonadal hpg mouse testes (3, 5, 18) , which fail to develop due to a functional deletion in the Gnrh1 gene (29, 49) .
The importance of FSHR activity in human spermatogenesis was suggested by a mutant FSHR (D567G) identified in a hypophysectomised man who retained spermatogenesis and fertility despite testosterone treatment alone with uncorrected gonadotropin deficiency (17) . The D567G substitution in the third cytoplasmic loop resembled ligand-independent activating mutations in related LH (23) and TSH (39) receptors, so it was proposed that FSHR*D567G provided constitutive FSHindependent activity (17) . Verification of the activating status of this FSHR mutation has proved difficult using in vivo (36) or in vitro (21, 45) models. We found that Sertoli cell-specific transgenic (Tg) FSHR*D567G expression increased FSH-responsive Sertoli and spermatogonia numbers in gonadotropindeficient hpg (Gnrh1 Ϫ/Ϫ ) (3, 19) and normal mice (2) . Testosterone production was increased in TgFSHR*D567G hpg mice, and we proposed that increased Sertoli cell FSHR activity had a paracrine effect on Leydig cells (19) .
An untested caveat of our TgFSHR*D567G model was that Sertoli cell overexpression of FSHR, shown by increased specific FSH binding to testis membranes and FSH-stimulated intracellular cAMP (19) , may elevate constitutive cell signaling and in vivo activity independently of the D567G mutation per se. Increased cellular expression of certain wild-type G protein-coupled receptors can elevate basal signaling (e.g., increased cAMP) in the absence of cognate ligands (10, 31, 51) . Other recent studies identified FSHR mutations that alter glycoprotein hormone specificity, associated with rare cases of ovarian hyperstimulation syndrome (12, 35, 48, 53) , including a related D567N mutation (48) . In cultured COS-7 cells, expression of human FSHR*D567G or other position 567 substitutions allowed high doses of recombinant TSH or hCG to elevate intracellular cAMP levels (35, 48) . However, wildtype human FSHR expression in vitro also increased promis-cuous glycoprotein hormone stimulation of cAMP production in COS-7 (7, 12, 35) or HEK 293 cells (43) , suggesting that FSHR overexpression alone may provide constitutive activity or promiscuous glycoprotein hormone binding. Conversely, mouse FSHR haploinsufficiency (FSHR ϩ/Ϫ ) produced small but significant changes to sperm quality, suggesting subtle changes to FSHR signaling effect testis function (20) . Therefore, we have now determined the in vivo gonadal consequence of Tg overexpression of wild-type human FSHR, specifically testing whether FSHR overexpression confers elevated FSHlike or androgenic testicular activity in gonadotropin-deficient hpg mice and comparing signaling activity of Tg wild-type FSHR vs. FSHR*D567G overexpression in Sertoli cells. We reveal that Tg FSHR overexpression did not direct significant testis or Sertoli cell activity independently of FSH, while providing evidence that in vivo FSH-independent intracellular signaling, increased steroidogenesis, and promiscuous ligandactivation due to FSHR*D567G expression is mediated via the specific mutation.
MATERIALS AND METHODS

Preparation of human TgFSHRwt mice.
The human wild-type FSHRwt transgene was prepared by modification of the Abpa-FSHR DNA construct used to prepare TgFSHR*D567G mice, previously referred to as Tg-FSHR ϩ (19) and Tg(Abpa-FSHR*D567G)1Cmal mice (2). A 1.4-kb BlpI DNA fragment from TgFSHR*D567G with the single nucleotide mutation was replaced with a corresponding BlpI fragment containing wild-type human FSHR cDNA sequence (confirmed by automated Dye-deoxy sequencing) by standard subcloning. The Abpa-FSHR DNA construct was linearized with SacII and KpnI, purified by agarose gel electrophoresis, and microinjected into mouse oocytes (2-3 ng/l, 10 mM Tris ⅐ HCl, pH 7.4, 0.1 mM EDTA) as described (5, 19) . TgFSHR founders and offspring were identified by PCR analysis of genomic tail DNA by using primers (FR1 and FR2) as previously described (19) . Two independent TgFSHR lines were established, Tg(Abpa-FSHR)1 and Tg(Abpa-FSHR)2, referred to hereafter as TgFSHRwt1 and TgFSHRwt2. Animals were housed under controlled conditions (12:12-h light-dark cycle, 19 -22°C) with ad libitum access to food and water. Mice expressing TgFSHRwt or TgFSHR*D567G on a gonadotropin-deficient hypogonadal hpg (Gnrh1 Ϫ/Ϫ ) background were obtained by crossbreeding heterozygote Gnrh1 ϩ/Ϫ animals, determined by detection of wild-type (wt) or disrupted Gnrh1 gene PCR products as described (5, 19) . All animal procedures were approved by the Animal Welfare Committee of the Sydney South West Area Health Service and performed in accordance with the National Health and Medical Research Council code of practice for the care and use of animals and the NSW Animal Research Act (1985) .
Testicular gene expression and histology. For testicular histology or RNA isolation, tissue was collected from anaesthetized 9-to 10-wk-old animals after terminal cardiac exsanguination as described (2, 19) . Total testis RNA was obtained from fresh tissue, using TRI reagent (Sigma) as recommended. Testicular TgFSHRwt RNA expression was confirmed by RT-PCR analysis, using primers and PCR conditions designed not to amplify endogenous mouse Fshr (19) . Leydig cell maturity was assessed by RT-PCR, using testis cDNA and published primers to detect Hsd3b6 [adult Leydig (37) ] and Leydigspecific Lhr expression (14) . Mouse actin RNA was detected as an internal sample control (19) . First-strand cDNA synthesis was performed using the SuperScript III First-Strand Synthesis System for RT-PCR (Invitrogen). No-reverse-transcriptase (no-RT) controls were included for all PCR reactions. Testis mRNA expression levels of Sertoli cell-specific Rhox5 or markers for acquired Leydig cell steroidogenic potential, Star, Cyp11a1, and Cyp17a1, were determined by quantitative real-time PCR analysis of cDNAs, using a RotorGene 2000 (Corbett Research, Sydney, Australia) and published [Rhox5 and Cyp11a1 (37)] and prevalidated primers (Star, Cyp17a1, SupperArray Biosci., Frederick, MD) with RT 2 SYBR Green qPCR master mix (SA Biosciences) as recommended. Mouse Wbscr1 primers validated for the testis (38) were used as a housekeeping gene to standardize relative transcript expression levels in different samples (n ϭ 3 per group), assigning standards an arbitrary value. For testicular histology, tissue from 9-to 10-wk-old animals were fixed, weighed, and prepared as described (2), and 3-m sections were cut using a Polycut S microtome (Reichert Jung, Nossloch, Germany) and then stained with 0.5% toluidine blue (Amerecso).
Testosterone treatment. Anesthetized 21-day-old Tg or non-Tg littermates/age-matched hpg males (n ϭ 4 -6 mice/group) received a subdermal 1-cm Silastic implant containing crystalline testosterone (T) as described (2, 18, 19) . After 6 wk of T treatment, serum was collected from anesthetized animals by terminal cardiac exsanguination, and testis were collected and weighed as described above.
Testicular FSH binding assay. Specific binding of 125 I-labeled FSH to testis membranes was determined as described (19) . Briefly, weighed testes from immature mice were homogenized in 0.5 ml of assay buffer (40 mM Tris ⅐ HCl, 5 mM MgSO4, 0.1% BSA) on ice and centrifuged at 11,000 g for 20 min at 4°C, and membrane pellets were stored at Ϫ80°C. Thawed membrane samples were resuspended in 100 l of assay buffer (2-4 mg of tissue) and duplicate tubes incubated with 50 l of 125 I-rFSH I-9 (10,000 cpm/tube) for 6 h at 35°C for maximal binding with or without excess rat FSH (20 g RP1-NIH). After addition of 1 ml of assay buffer, the tubes were centrifuged (11,000 g, 3 min) at 4°C, supernatant was discarded, and pellets were washed again and then counted. Maximal specific binding was nonspecific binding (excess unlabeled hormone) subtracted from total (without excess).
Sertoli cell culture and cAMP analysis. Sertoli cells were isolated from testes of 11-to 14-day-old mice as described previously (19) . Briefly, collagenase and trypsinization removed interstitial and most peritubular cells, and then Sertoli cell aggregates were cultured (48-well plates, Costar) in serum-free MEM (GIBCO-BRL) supplemented with 5 ng/ml sodium selenate, 3 g/ml cytosine arabinoside, 5 g/ml human transferrin, and 1 nM hydrocortisone at 37°C in a humidified incubator with 5% CO2. After 3 days, remaining germ cells were removed by hypotonic treatment with 20 mM Tris buffer for 2 min (15) . For cAMP analysis, on day 4, medium was replaced with serum-free supplemented MEM containing phosphodiesterase inhibitor (0.5 mM IBMX), and cells were untreated or stimulated with 300 ng/ml recombinant human (rh)FSH (Serono), 30 mIU/ml rhTSH (Genzyme), or 300 IU/ml hCG (Pregnyl, Organon; contaminating TSH and FSH measured by Roche E170 modular immunoassay) for 1 h at 37°C. Incubations were terminated by removal of medium and addition of 0.1 M HCl for 20 min at 4°C. Cell extracts were collected and stored at Ϫ80°C for cAMP analysis. The cAMP content of Sertoli cell extracts (i.e., intracellular levels) were determined by radioimmunoassay as described (19) , and sample cAMP levels were normalized for total protein levels by the Bradford method (9).
Statistics. Data were evaluated by analysis of variance followed by suitable post hoc tests using NCSS software (Statistical Analysis and Data Analysis Software, Kaysville, UT). Data are presented as means Ϯ SE. P values Ͻ 0.05 were considered statistically significant.
RESULTS
TgFSHRwt mice.
Nine TgFSHRwt founders were prepared using the Abpa-FSHRwt DNA construct to direct testicular Sertoli cell-specific Tg human FSHR expression via the rat Abpa promoter (19) . Independent TgFSHRwt lines were established using hemizygous Tg parents, which produced Tg offspring at levels (48%) close to the expected 50% frequency.
Hemizygous TgFSHRwt ϩ/Ϫ hpg mice were obtained from Gnrh1 ϩ/Ϫ parents at a level (11% of offspring) close to the expected frequency (12.5%), and transgenic lines were tested for testicular TgFSHR mRNA expression by RT-PCR, as described (19) . Two lines, TgFSHRwt1 and TgFSHRwt2, exhibiting TgFSHR mRNA expression in testes from normal and hpg adult males (Fig. 1A) (Fig. 1B) , all significantly elevated more than twofold relative to non-Tg control testes. Testicular overexpression of TgFSHRwt in normal (Gnrh1 ϩ/Ϫ or Gnrh1 ϩ/ϩ ) males had no effect on testis size or serum T levels and did not disrupt normal reproductive function (data not shown). The in vivo effects of TgFSHRwt overexpression were further determined using FSH-deficient hpg mice. Testis weights of mature TgFSHRwt ϩ/Ϫ hpg mice from the independent lines were equivalent to non-Tg hpg littermates, unlike the over twofold relative increase in TgFSHR*D567G hpg testes (Fig. 2) . Gonadal actions of TgFSHRwt expression were tested in combination with T treatment (1-cm implant) corresponding to a maximal androgen response in the hpg testis (47) . Testes of T-treated TgFSHRwt ϩ/Ϫ hpg mice remained equivalent in weight to the maximal response of non-Tg hpg testes to T alone (Fig. 2) , whereas expression of mutant TgFSHR*D567G in hpg testes produced an additive effect with T treatment on testicular weight as previously reported (19) .
Overexpression of TgFSHRwt in hpg testes had no detectable effect on cellular morphology in interstitial tissue or seminiferous tubules (Fig. 3) , which remained equivalent to non-Tg hpg controls exhibiting tubules with immature-like Sertoli cells, no lumen, and an undeveloped germinal epithelium layer with spermatogenic arrest at the zygotene-pachytene stage of meiosis compared with normal testes (Fig. 3) . In comparison, enlarged TgFSHR*D567G testes had numerous meiotic pachytene spermatocytes and sparse numbers of postmeiotic elongated spermatids (Fig. 3) . Equivalent hpg-like histology was found in numerous TgFSHwt1 or TgFSHRwt2 hpg testes.
Expression of TgFSHRwt had no significant effect on expression levels of the androgen-responsive and Sertoli-specific Rhox5 gene (or Pem) in hpg mouse testes (26) , unlike the higher (P Ͻ 0.01) Rhox5 expression found in TgFSHR*D567G hpg testes (Fig. 4) . Lower Rhox5 expression in wt compared with TgFSHR*D567G hpg testes is likely to reflect the increased germ cell population in larger wt testes diluting Sertoli cell-specific signals. Sertoli cell TgFSHR*D567G in hpg mice increased (P Ͻ 0.05) the testis expression of Cyp11a1 [cytochrome P-450 side-chain cleavage (P450 scc)] and Star (steroidogenic acute regulatory protein) transcripts, with a variable nonsignificant rise in Cyp17a1 (cytochrome P-450, family 17, subfamily a, polypeptide 1), all key enzymes in steroid synthesis (34) . Lower expression of these transcripts in wt compared with TgFSHR*D567G hpg testes may reflect increased germ cell populations in larger wt testes diluting any Leydig cell-specific signal. Testicular expression of Hsd3b6, a marker for adult Leydig cells (8), was not increased by TgFSHwt or TgFSHR*D567G expression in hpg mice, with Lhr (LH receptor) expression confirming detection of Leydig cell tran- . A: expression of Tg FSHR mRNA determined by RT-PCR analysis using total testis RNA from mature (9-to 10-wk-old) TgFSHRwt (ϩ) and non-Tg (Ϫ) mice of the normal Gnrh1 ϩ/ϩ (ϩ) or Gnrh1 Ϫ/Ϫ hpg (Ϫ) genotype as shown. Actin mRNA was detected as an internal control. Amplified cDNA fragments visualized after agarose gel electrophoresis demonstrated that TgFSHRwt1 (A) and TgFSHRwt2 (not shown) males expressed TgFSHRwt mRNA in both normal and hpg testes. B: cellular expression of Tg FSHR was confirmed by specific 125 I-labeled FSH binding to testis homogenates from 10-to 12-day mice as described in MATERIALS AND METHODS. Testes from TgFSHRwt1 and TgFSHRwt2 lines had significantly increased levels of maximal specific 125 I-FSH binding relative to non-Tg testes, each comparable to increased specific binding in TgFSHR*D567G testes. scripts (Fig. 4) . Equivalent expression patterns were found in TgFSHwt1 or TgFSHRwt2 hpg testes.
TgFSHRwt actions in isolated sertoli cells. Sertoli cells were isolated from immature TgFSHRwt, TgFSHR*D567G, and non-Tg littermate controls to examine intracellular cAMP levels produced in the presence of overexpressed TgFSHRwt or TgFSHR*D567G. Sertoli cells were stimulated with a dose of rhFSH that produces a maximal cAMP response in Tg or non-Tg Sertoli cells (19) . The response of cAMP to FSH treatment was twofold greater (P Ͻ 0.005) in TgFSHRwt compared with control non-Tg Sertoli cells (Fig. 5) and was 40% higher (P Ͻ 0.05) relative to TgFSHR*D567G Sertoli cells. However, basal levels of intracellular cAMP (no FSH stimulation) were not significantly increased in cultured TgFSHRwt compared with non-Tg Sertoli cells, unlike the increased (2-fold, P Ͻ 0.001) basal cAMP levels found in TgFSHR*D567G Sertoli cells (Fig. 5) . Equivalent findings were found using TgFSHwt1 or TgFSHRwt2 Sertoli cells in experiments repeated three times.
Recent studies suggested that the FSHR*D567G and other position 567 mutations altered specificity to related glycoprotein hormones TSH and hCG (35, 48) . We examined the ligand specificity of Tg Sertoli cells overexpressing FSHRwt vs. the mutant FSHR*D567G using rhTSH and hCG at doses previously found to stimulate maximal cAMP responses in cultured cells (35, 48) . The TgFSHRwt Sertoli cells showed no significant cAMP response to 30 mIU/ml TSH or 300 IU/ml hCG (Fig. 5) . The hCG preparation at this dose contained TSH (35 nIU/ml) and FSH (ϳ0.1 ng/ml) at levels well below those expected to stimulate Sertoli cell cAMP responses. In TgFSHR*D567G Sertoli cells, the same dose of TSH had a small but significant effect by elevating cAMP levels 40% (P Ͻ 0.05) relative to basal cAMP levels (Fig. 5) . In contrast, hCG treatment of TgFSHR*D567G Sertoli cells increased cAMP levels sixfold (P Ͻ 0.001) compared with basal levels, which was equivalent to 40% of the FSH-stimulated cAMP response. Equivalent findings were found in experiments repeated three times.
DISCUSSION
We have determined the in vivo actions of Tg overexpression of human FSHRwt vs. mutant FSHR*D567G in Fig. 4 . Testicular expression of indicated transcripts using total testis RNA from 9-to 10-wk-old mice. A: relative expression levels of androgen-regulated and Sertoli cell-specific Rhox 5, or key steroidogenic Leydig cell markers Cyp11a1, Cyp17a1, and Star in TgFSHRwt (light gray), TgFSHR*D567G (filled), and non-Tg hpg (open) mice and non-Tg Gnrh1 ϩ/ϩ (dark gray) testes were determined by real-time PCR analysis, as described in MATERIALS AND METHODS. Steroidogenic markers were elevated in TgFSHR*D567G relative to TgFSHRwt and non-Tg hpg testes. *Significant differences (P Ͻ 0.05). B: expression of an adult Leydig cell marker Hsd3b6 and Leydig cell-specific Lhr in Tg (ϩ) and non-Tg (Ϫ) mice of the normal Gnrh1 ϩ/ϩ (ϩ) or Gnrh1
hpg (Ϫ) genotype were determined by RT-PCR analysis as described in MATERIALS AND METHODS. Actin mRNA was detected as an internal control and end lanes (right) show no-RT controls. Hsd3b6 expression was not detected in Tg hpg mice, demonstrating the absence of adult Leydig cells. mouse Sertoli cells. Targeted overexpression of TgFSHRwt or TgFSHR*D567G each increased specific FSH binding to testis membranes, but only TgFSHR*D567G expression stimulated testicular development or markers of acquired steroidogenic potential in FSH-deficient hpg males. In isolated Sertoli cells, expression of TgFSHR*D567G elevated basal cAMP levels and promiscuous glycoprotein hormone activation. In contrast, although Sertoli cell TgFSHRwt expression augmented the FSH-induced cAMP response, it was not able to increase constitutive intracellular cAMP signaling or allow promiscuous glycoprotein hormone activity. We had proposed (19) that the human FSHR D567G mutation provided autonomous receptor signaling independently of FSH when expressed in Tg mice, yet it remained possible that Tg overexpression of FSHR and not the mutation per se provided increased signaling. In the present study, we determined the in vivo consequence of TgFSHRwt targeted to testicular Sertoli cells via the rat Abp promoter (19) . Tg overexpression of FSHRwt increased (ϳ2-fold) the total specific FSH binding to testis membranes and FSH-induced intracellular cAMP response in isolated Sertoli cells relative to non-Tg controls, effects that were comparable to those due to Tg FSHR*D567G. However, TgFSHRwt did not replicate the increased basal intracellular cAMP levels found in unstimulated TgFSHR*D567G Sertoli cells. Thus, Tg FSHR overexpression alone did not appear to account for the increased constitutive signaling provided by the Tg mutant FSHR*D567G.
Overexpression of TgFSHR*D567G in Sertoli cells allowed promiscuous glycoprotein hormone binding, as hCG and TSH each increased intracellular cAMP at doses that produced maximal effects in transformed cell lines expressing human FSHR isoforms, including the D567G (or similar D567N) substitution (12, 35, 48) . In contrast, Sertoli overexpression of TgFSHRwt did not allow promiscuous activation (i.e., elevated cAMP) by either hCG or TSH. Failure of TSH to stimulate TgFSHRwt Sertoli cells differed from the reported TSH-induced cAMP responses in HEK 293 (35, 43) or COS-7 (7) cells expressing human wild-type FSHR. This TSH-induced FSHR activity may reflect different levels or type of G proteins in transformed lines compared with primary Sertoli cells, or very high FSHR expression levels, noting that 30 mIU/ml TSH produced a smaller cAMP response (40% above basal levels) in TgFSHR*D567G Sertoli cells compared with the cAMP responses (Ͼ2-fold basal) in previous studies (35, 48) . The lack of cAMP responses in hCG or TSH-treated TgFSHRwt Sertoli cells indicates that promiscuous glycoprotein hormone activation of mutant FSHR is not due to elevated expression levels alone.
Tg human FSHRwt had no detectable effect on the development in FSH-deficient hpg testes, shown by the equivalent size and histology of TgFSHRwt and non-Tg hpg testes, unlike the FSH-like cellular response in larger TgFSHR*D567G hpg testes. Furthermore, T-treated TgFSHRwt hpg testes lacked the additive FSH-like effect observed in treated TgFSHR*D567G hpg testes. Expression of the androgen-regulated Sertoli-specific transcript Rhox5 (26) was increased in TgFSHR*D567G hpg testes, consistent with higher Sertoli cell numbers in TgFSHR*D567G compared with non-Tg hpg testes (3). In contrast, TgFSHRwt and non-Tg hpg testes displayed similar levels of Rhox5 expression, significantly below the expression found in TgFSHR*D567G hpg testes. Thus, the equivalent development of TgFSHRwt and non-Tg hpg testes, together with the similar Rhox5 expression, demonstrate that overexpression of TgFSHRwt alone did not stimulate Sertoli or major germ cell development in vivo.
We proposed that Sertoli cell expression of TgFSHR*D567G provided paracrine signaling to steroidogenic Leydig cells in the absence of circulating FSH, based on higher T levels in TgFSHR*D567G hpg testes relative to non-Tg hpg testes (19) . We now reveal that expression of Cyp11a1 (cytochrome P-450 sidechain cleavage) and Star (steroidogenic acute regulatory protein) transcripts were increased, with a trend for increased Cyp17a1, in TgFSHR*D567G hpg compared with non-Tg hpg testes, which was not observed in TgFSHRwt hpg testes. Elevated markers for acquired Leydig cell steroidogenesis in LH-deficient TgFSHR*D567G hpg mice (19) provide strong evidence for constitutive (gonadotropin-independent) FSHR*D567G-mediated paracrine signaling between Sertoli and Leydig cells. The absence of upregulated Hsd3b6 expression, a marker for adult mouse Leydig cells (8, 38) , in TgFSHR*D567G hpg testes confirms absent LH stimulation and was consistent with the presence of immature-like lipid-laden Leydig cells (33) . Therefore, we propose that elevated androgen production (2, 19) due to Tg FSHR*D567G expression is provided by an immature population of Leydig cells. Furthermore, the TgFSHRwt hpg males reveal that Tg FSHR overexpression alone does not provide sufficient paracrine activity to upregulate testicular androgen production.
Normal (Gnrh1 ϩ/ϩ or Gnrh1 ϩ/Ϫ ) male or female mice expressing TgFSHRwt were found to be fertile and exhibited normal gonadal size. The overexpression of FSHR was recently reported to activate oncogenic pathways in ovarian epithelial cells (11) , but the incidence of ovarian cancer was not increased in either TgFSHR*D567G or TgFSHRwt females (C. Allan, unpublished observations). No detectable effect of TgFSHR*D567G or TgFSHRwt on female reproduction may reflect lower levels of ovarian relative to testicular Tg expression directed by the rat Abpa promoter (19) , supported by the absence of ovarian development in TgFSHR*D567G hpg females (19) . Furthermore, unlike pregnant humans and higher primates that express placental chorionic gonadotropin at very high levels (30), mice do not have an equivalent placentalderived gonadotropin and lack the possibility for gestational promiscuous glycoprotein hormone activation of the mutant FSHR*D567G causing ovarian hyperstimulation.
In summary, our current work demonstrated that Tg FSHR overexpression did not provide sufficient activity to induce an FSH-independent constitutive Sertoli cell response. This Tg paradigm has revealed that Sertoli cell FSHR*D567G but not FSHRwt overexpression elevated gene expression of steroidogenic enzymes required for testicular androgen synthesis, independent of circulating gonadotropins. Finally, this in vivo approach has provided strong evidence that altered glycoprotein hormone specificity and constitutive receptor activation by FSHR*D567G is due to the intracellular D567G substitution rather than FSHR overexpression per se.
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